JPWO2022150628A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022150628A5 JPWO2022150628A5 JP2023541058A JP2023541058A JPWO2022150628A5 JP WO2022150628 A5 JPWO2022150628 A5 JP WO2022150628A5 JP 2023541058 A JP2023541058 A JP 2023541058A JP 2023541058 A JP2023541058 A JP 2023541058A JP WO2022150628 A5 JPWO2022150628 A5 JP WO2022150628A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- subject
- pharma
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 238000011518 platinum-based chemotherapy Methods 0.000 claims 2
- 102200006538 rs121913530 Human genes 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 239000007909 solid dosage form Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135449P | 2021-01-08 | 2021-01-08 | |
| US63/135,449 | 2021-01-08 | ||
| US202163189625P | 2021-05-17 | 2021-05-17 | |
| US63/189,625 | 2021-05-17 | ||
| PCT/US2022/011673 WO2022150628A1 (en) | 2021-01-08 | 2022-01-07 | Use of a kras g12c inhibitor in treating cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024502446A JP2024502446A (ja) | 2024-01-19 |
| JPWO2022150628A5 true JPWO2022150628A5 (https=) | 2025-01-15 |
| JP2024502446A5 JP2024502446A5 (https=) | 2025-01-15 |
Family
ID=80222156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541058A Pending JP2024502446A (ja) | 2021-01-08 | 2022-01-07 | 癌の治療におけるｋｒａｓ ｇ１２ｃ阻害剤の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240091230A1 (https=) |
| EP (2) | EP4650006A3 (https=) |
| JP (1) | JP2024502446A (https=) |
| AU (1) | AU2022205969A1 (https=) |
| CA (1) | CA3206523A1 (https=) |
| MX (1) | MX2023007918A (https=) |
| TW (1) | TWI906448B (https=) |
| WO (1) | WO2022150628A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| WO2019213516A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201992781A1 (ru) | 2017-05-22 | 2020-04-01 | Эмджен Инк. | Ингибиторы g12c kras и способы их применения |
| EP3738593A1 (en) * | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| NZ782284A (en) | 2019-05-21 | 2024-11-29 | Amgen Inc | Solid state forms |
-
2022
- 2022-01-07 MX MX2023007918A patent/MX2023007918A/es unknown
- 2022-01-07 WO PCT/US2022/011673 patent/WO2022150628A1/en not_active Ceased
- 2022-01-07 US US18/270,581 patent/US20240091230A1/en active Pending
- 2022-01-07 TW TW111100657A patent/TWI906448B/zh active
- 2022-01-07 EP EP25206294.8A patent/EP4650006A3/en active Pending
- 2022-01-07 CA CA3206523A patent/CA3206523A1/en active Pending
- 2022-01-07 AU AU2022205969A patent/AU2022205969A1/en active Pending
- 2022-01-07 JP JP2023541058A patent/JP2024502446A/ja active Pending
- 2022-01-07 EP EP22703115.0A patent/EP4274579A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022009090A5 (https=) | ||
| CN103945849B (zh) | 癌症的联合治疗 | |
| JP2024015120A5 (https=) | ||
| JP2021098728A5 (https=) | ||
| CN114641293A (zh) | 一种fgfr抑制剂的用途 | |
| JP2019503365A5 (https=) | ||
| CN101360495B (zh) | 对癌症病人给药mTOR抑制剂 | |
| CN103533940A (zh) | 治疗晚期实体瘤的方法 | |
| WO2017118401A1 (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| JP7523879B2 (ja) | 医薬組成物 | |
| JP2023102786A5 (https=) | ||
| CN112584834B (zh) | 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物 | |
| JP2004525143A5 (https=) | ||
| CN101357134A (zh) | 抗肿瘤效果增强剂和抗肿瘤剂 | |
| CN119497618A (zh) | 药物组合产品以及组合疗法 | |
| JPWO2022150628A5 (https=) | ||
| JP2022177119A5 (https=) | ||
| TW201716064A (zh) | 供治療癌症之口服投予紫杉醇及Ｐ－ｇｐ抑制劑的治療性組合 | |
| JP2021503448A5 (https=) | ||
| JP2021091608A5 (https=) | ||
| CA2569739C (en) | Antitumor effect potentiator, antitumor preparation, and method for treating cancer | |
| JP4707668B2 (ja) | オキソプラチン、その塩および誘導体を含む医薬組成物 | |
| JPWO2022074124A5 (https=) | ||
| JP2005502690A5 (https=) | ||
| CN102309491B (zh) | 一种替加氟、吉美斯特复方注射液 |